TheraRadar

Pharma Intelligence, Simplified

Landscape → CNS

Parkinson's Disease

559 clinical trials

187 active
/
559 total (since 2015)
73
Phase 1 Active
224 total
100
Phase 2 Active
280 total
24
Phase 3 Active
80 total
16
Phase 4 Active
49 total

Top Sponsors (Industry)

Sorted by active Active Done Failed
iRegene Therapeutics Co., Ltd. 4 0 0
Luye Pharma Group Ltd. 3 8 0
Roche 3 1 0
AbbVie 2 11 1
NeuroDerm Ltd. 2 3 1
Shanghai Vitalgen BioPharma Co., Ltd. 2 0 0
Prevail Therapeutics 2 0 0
iCamuno Biotherapeutics Ltd. 2 0 0
XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd. 2 0 0
Gain Therapeutics, Inc. 2 0 0
AskBio Inc 2 0 0
InnoMedica Schweiz AG 2 0 0
Biogen 1 3 3
Sumitomo Pharma America, Inc. 1 5 0
H. Lundbeck A/S 1 3 2
NCT06944522 RECRUITING
A Study to Investigate the Efficacy and Safety of Bemdaneprocel in Adults Who Have Parkinson's Disease
BlueRock Therapeutics n=102
NCT07284784 RECRUITING
A Study of Buntanetap in Participants With PD
Annovis Bio Inc. n=500
NCT07316296 RECRUITING
Pharmacologically Modulating the Noradrenergic Arousal System to Reduce Freezing of Gait in Parkinson's Disease: a Multi-centre and Multi-modal Approach
Radboud University Medical Center n=60
NCT07395531 NOT YET RECRUITING
Effect of Repetitive Bihemispheric Anodal Transcranial Direct Current Stimulation on Motor Function of Patients With Parkinson's Disease
Dr. Ram Manohar Lohia Hospital n=30
NCT04706910 RECRUITING
18F-DOPA II - PET Imaging Optimization
University of Alberta n=800
NCT07174310 RECRUITING
A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease
Hoffmann-La Roche n=900
NCT06785298 RECRUITING
Fexofenadine as Adjuvant Therapy in Parkinson Disease
Tanta University n=46
NCT06976268 RECRUITING
A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease
Biohaven Therapeutics Ltd. n=550
NCT06553027 RECRUITING
To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications
Cerevance n=330
NCT07229664 RECRUITING
Vinpocetine in Patients With Parkinsonian Disease
Tanta University n=60
NCT07229651 RECRUITING
Metformin in Parkinson Disease
Tanta University n=60
NCT07207057 RECRUITING
Edmond J. Safra Accelerating Clinical Trials in Parkinson's Disease: A Multiarm Multi-stage Platform Trial
University College, London n=1,200
NCT07151378 NOT YET RECRUITING
Intestinal Levodopa + Entacapone Therapy (Lecigon®) to Counteract Dopaminergic Desensitization and Neuropsychiatric Complications in Parkinson's Disease
University Hospital Tuebingen n=150
NCT04750226 ACTIVE NOT RECRUITING
Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson's Disease
AbbVie n=118
NCT04379050 ACTIVE NOT RECRUITING
Extension Study To Evaluate Safety And Tolerability Of 24-Hour Daily Exposure Of Continuous Subcutaneous Infusion of ABBV-951 In Adult Participants With Parkinson's Disease
AbbVie n=130
NCT04664634 RECRUITING
A Digital Therapeutic Platform for Swallowing and Drooling Problems in Parkinson's
Northwestern University n=60
NCT07055958 ACTIVE NOT RECRUITING
Effect of Metformin as Add-on Therapy in Levodopa Treated Parkinson's Disease Patients
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh n=74
NCT02339064 ACTIVE NOT RECRUITING
Infusion of Apomorphine: Long-term Safety Study
MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals n=99
NCT04006210 ACTIVE NOT RECRUITING
Efficacy, Safety and Tolerability Study of ND0612 vs. Oral Immediate Release Levodopa/Carbidopa (IR-LD/CD) in Subjects With Parkinson's Disease Experiencing Motor Fluctuations
NeuroDerm Ltd. n=381
NCT06596876 RECRUITING
A Study to Evaluate the Efficacy and Safety of HRG2010 in Parkinson's Disease With Motor Fluctuations
Jiangsu HengRui Medicine Co., Ltd. n=450
NCT05778617 RECRUITING
Ambroxol to Slow Progression in Parkinson Disease
University College, London n=330
NCT05576818 RECRUITING
Effect of Synbiotic as an Adjuvant Therapy in the Treatment of Parkinson's Disease
Tanta University n=66
NCT06120049 RECRUITING
[18F]-MFBG Versus [123I]-MIBG and [18F]-PE2I in PD vs. MSA and DLB vs. AD
prof. dr. Koen Van Laere n=113
NCT06113640 RECRUITING
Montelukast in Parkinson Disease
Mostafa Bahaa n=60
NCT06068465 COMPLETED
A Study of the Safety and Efficacy of Pimavanserin in Patients With Parkinson's Disease Psychosis
Tasly Pharmaceutical Group Co., Ltd n=248
NCT04760769 COMPLETED
Open-label Trial in Parkinson's Disease (PD)
AbbVie n=992
NCT04223193 COMPLETED
Flexible-Dose Trial in Early Parkinson's Disease (PD)
AbbVie n=304
NCT04265209 COMPLETED
[18F] LBT-999 PET Compared to [123I]-FP/CIT SPECT to Distinguish Between Parkinson's Diseases and Essential Tremor
GE Healthcare n=152
NCT04226248 COMPLETED
CHIEF-PD (CHolinesterase Inhibitor to prEvent Falls in Parkinson's Disease)
University of Bristol n=600
NCT03568968 COMPLETED
A Randomized Controlled Trial of Nicotinamide Riboside Supplementation in Early Parkinson's Disease
Haukeland University Hospital n=410
NCT05116813 TERMINATED
Open-label Safety Study of Dipraglurant (ADX48621) in Patients With Parkinson's Disease Receiving Levodopa-based Therapy
Addex Pharma S.A. n=17
NCT04857359 TERMINATED
Dipraglurant (ADX48621) for the Treatment of Patients With Parkinson's Disease Receiving Levodopa-based Therapy
Addex Pharma S.A. n=25
NCT04201093 COMPLETED
Fixed-Dose Trial in Early Parkinson's Disease (PD)
AbbVie n=529
NCT04542499 COMPLETED
Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson's Disease With Motor Fluctuations (TEMPO-3)
AbbVie n=507
NCT05357989 COMPLETED
A Double-blind Study to Investigate Efficacy and Safety of Buntanetap Compared With Placebo in Participants With Early PD
Annovis Bio Inc. n=523
NCT04152655 WITHDRAWN
A Study of Efficacy and Safety of Idebenone Vs. Placebo in Prodromal Parkinson Disease
Second Affiliated Hospital, School of Medicine, Zhejiang University
NCT05611372 WITHDRAWN
Efficacy and Safety of Rasagiline in Prodromal Parkinson's Disease
Second Affiliated Hospital, School of Medicine, Zhejiang University
NCT05487300 COMPLETED
Effect of Levodopa on Cardiovascular Autonomic Function in Parkinson's Disease
University of Utah n=40
NCT03808675 COMPLETED
Aerobic Exercise in Parkinson's Disease
VA Office of Research and Development n=57
NCT05001217 COMPLETED
Chinese Herbal Medicine Treatment as Adjunct Therapy for Parkinson's Disease
Hong Kong Baptist University n=160
NCT03149809 COMPLETED
Behavioral or Solifenacin Therapy for Urinary Symptoms in Parkinson Disease
VA Office of Research and Development n=77
NCT05418673 TERMINATED
A Study to Assess if BIIB122 Tablets Are Safe and Can Slow Worsening of Early-Stage Parkinson's Disease in Participants With Specific LRRK2 Genetic Variants Between the Ages of 30 and 80 Using the Movement Disorder Society-Unified Parkinson's Disease Rating Scale
Biogen n=7
NCT02610231 COMPLETED
Long Term Study of Istradefylline in Subjects With Moderate to Severe Parkinson's Disease
Kyowa Kirin Co., Ltd. n=239
NCT03881371 COMPLETED
A Study to Evaluate the Efficacy and Safety of Safinamide, as add-on Therapy, in Idiopathic Chinese Parkinson's Disease (PD) Patients With Motor Fluctuations Treated With Stable Doses of Levodopa
Zambon SpA n=307
NCT02470780 COMPLETED
Treating Bacterial Overgrowth in Parkinson's Disease
University of Cincinnati n=4
NCT02549092 COMPLETED
A Study to Examine the Effect of Levodopa-Carbidopa Intestinal Gel (LCIG) Therapy Relative to That of Optimized Medical Treatment (OMT) on Non-motor Symptoms (NMS) Associated With Advanced Parkinson's Disease (PD)
AbbVie n=89
NCT02542696 COMPLETED
Open-Label Phase 3 Study to Examine the Long-Term Safety, Tolerability and Efficacy of APL-130277 for the Acute Treatment of "OFF" Episodes in Patients With Parkinson's Disease
Sumitomo Pharma America, Inc. n=496
NCT03781167 COMPLETED
A Study to Evaluate the Safety and Tolerability of ABBV-951 in Subjects With Parkinson's Disease (PD)
AbbVie n=244
NCT04193527 COMPLETED
A Study to Evaluate the Diagnostic Efficacy of DaTSCAN™ Ioflupane (123I) Injection in Single Photon Emission Computed Tomography (SPECT) for the Diagnosis of Parkinsonian Syndrome (PS) in Chinese Patients
GE Healthcare n=172
NCT03877510 COMPLETED
Open Label Extension (OLE) Study of the Safety and Clinical Utility of IPX203 in Parkinson's Disease (PD) Participants With Motor Fluctuations
Impax Laboratories, LLC n=419
NCT04571164 COMPLETED
A Study to Evaluate the Effectiveness and Safety of LY03003 in Patients With Early Primary PD
Luye Pharma Group Ltd. n=294
NCT03652870 COMPLETED
Antidepressants Trial in Parkinson's Disease
University College, London n=52
NCT03971617 TERMINATED
Clinical Trial to Evaluate the Safety and Tolerability of Hydrogen in Patients With Parkinson's Disease
Stony Brook University n=2
NCT03329508 COMPLETED
A Phase 3 Study With P2B001 in Subjects With Early Parkinson's
Pharma Two B Ltd. n=544
NCT03670953 COMPLETED
A Study to Evaluate the Safety and Efficacy of IPX203 in Parkinson's Disease Participants With Motor Fluctuations
Impax Laboratories, LLC n=630
NCT03829657 TERMINATED
Phase 3 Clinical Effect Durability of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure
Theravance Biopharma n=203
NCT03391882 COMPLETED
A Study of an Investigational Drug to See How it Affects the People With Parkinson's Disease Complicated by Motor Fluctuations ("OFF" Episodes) Compared to an Approved Drug Used to Treat People With Parkinson's Disease Complicated by Motor Fluctuations ("OFF" Episodes)
Sumitomo Pharma America, Inc. n=113
NCT04380142 COMPLETED
Study Comparing Continuous Subcutaneous Infusion Of ABBV-951 With Oral Carbidopa/Levodopa Tablets For Treatment Of Motor Fluctuations In Adult Participants With Advanced Parkinson's Disease
AbbVie n=174
NCT02601586 COMPLETED
Effects of PR Oxycodone and of Levodopa, vs Placebo, on Central Neuropathic Pain in Parkinson's Disease
University Hospital, Toulouse n=67
NCT02337764 COMPLETED
A Long-term, Phase 3 Study of TVP-1012 (1 mg) in Levodopa Treated Parkinson's Disease Participants
Takeda n=222
NCT02337751 COMPLETED
A Phase 3, Long-term, Extension Study of TVP-1012 (1 mg) in Early Parkinson's Disease Participants
Takeda n=198
NCT02337725 COMPLETED
A Phase 3 Study of TVP-1012 (1 mg) in Early Parkinson's Disease Patients
Takeda n=244
NCT02337738 COMPLETED
A Phase 2/3 Study of TVP-1012 at 0.5 mg or 1 mg in Levodopa Treated Parkinson's Disease Participants
Takeda n=404
NCT03042416 COMPLETED
18F-DOPA PET Imaging: an Evaluation of Biodistribution and Safety
University of Alberta n=400
NCT03473522 COMPLETED
Effects of tDCS Combined With Therapeutic Exercises in Patients With Parkinson's Disease.
Alessandra Tanuri Magalhães n=30
NCT03773796 COMPLETED
Nabilone for Non-motor Symptoms in Parkinson's Disease
Medical University Innsbruck n=22
NCT03759132 COMPLETED
Effects of Transcranial Direct Current Stimulation on Postural Control
Universidade Federal do Piauí n=18
NCT02799381 COMPLETED
A Study Comparing Efficacy of Levodopa-Carbidopa Intestinal Gel/Carbidopa-Levodopa Enteral Suspension and Optimized Medical Treatment on Dyskinesia in Subjects With Advanced Parkinson's Disease (DYSCOVER)
AbbVie n=63
NCT03876327 COMPLETED
Fecal Microbiota Transplantation As a Potential Treatment for Parkinson's Disease
Soroka University Medical Center n=10
NCT04287543 WITHDRAWN
Melatonin on Clock Genes in Parkinson's Disease
Instituto Mexicano del Seguro Social
NCT02469090 COMPLETED
Efficacy, Safety and Tolerability Study of APL-130277 for the Acute Treatment of OFF Episodes in Patients With Parkinson's Disease
Sumitomo Pharma America, Inc. n=141
NCT02642393 COMPLETED
Study of Urate Elevation in Parkinson's Disease, Phase 3
Michael Alan Schwarzschild n=298
NCT04455555 COMPLETED
Efficacy and Safety of Rotigotine in the Treatment of Patients With Early Stage of Primary Parkinson's Disease
Peking University Third Hospital n=294
NCT04451096 COMPLETED
Probiotics-prebiotic Fiber Therapy in Parkinson's Disease Patients With Constipation
National University of Malaysia n=48
NCT03987750 WITHDRAWN
Safinamide for Levodopa-induced Dyskinesia (PD-LID)
Zambon SpA
NCT02782481 WITHDRAWN
A Clinical Study Investigating the Efficacy, Tolerability, and Safety of Continuous Subcutaneous ND0612 Infusion Given as Adjunct Treatment to Oral Levodopa in Patients With Parkinson's Disease With Motor Fluctuations
NeuroDerm Ltd.
NCT02242487 COMPLETED
Twelve Month Safety and Efficacy Study of CVT-301 In Parkinson's Disease Patients With OFF Episodes
Acorda Therapeutics n=325
NCT02352363 COMPLETED
Randomized Safety Study of CVT-301 Compared to an Observational Control Group
Acorda Therapeutics n=408
NCT03051607 TERMINATED
Safety and Tolerability of Tozadenant as Adjunctive Therapy in Levodopa-Treated Patients With Parkinson's Disease.
Biotie Therapies Inc. n=66
NCT02453386 TERMINATED
Safety and Efficacy Study of Tozadenant to Treat End of Dose Wearing Off in Parkinson's Patients
Biotie Therapies Inc. n=449

Data: ClinicalTrials.gov